Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: No mention of the cost of treatment. This is important if the surgery is not a permanent fix for acute sinusitis. Repeated operations and continued medications need to be compared to cost for traditional surgery. No quantitative estimate of the benefits of the new procedure. There was a study of 10 people that found “no safety concerns”, but readers should be told more about this very small group. What were the long term outcomes and did these patients eventually have to have further sinuplasty, more invasive surgery or continue to take medications to relieve sinusitits? The story mentions that a larger, randomized trial is underway to better understand the risks and benefits of sinuplasty compared to medication and traditional sinus surgery. Mentions that more information is needed and no one knows if balloon sinuplasty works as well as the more traditional surgical option for chronic sinusitis. Mentions that general anesthesia is still needed for balloon procedure and this comes with its own set of health risks. There isn’t much evidence for the story to report. The story did stress the importance of a randomized trial underway comparing medication, traditional sinus surgery and the newer balloon sinuplasty. Story describes this trial and the need for further evidence before this new procedure can be widely recommended. Mentions that this procedure should not have been FDA approved with so little quality evidence. No evidence of disease mongering. The story mentions that this procedure would be for chronic, not acute sinunitis and describes how these are different. Good balance of information on treatment options with input from otolaryngologists not affliated with the makers of the device who are able to provide perspective on the new procedure. They mention that further study is needed. There is a note that one of the physicans studying the new sinuplasty has no financial ties to Acclarent, maker of the balloon devices used in this type of sinuplasty. Mentions that this form of sinuplasty is not for everybody and that it may not prevent the need for more comprehensive surgery in which bone and tissue are removed. There is mention of other options including medication and the more traditional surgery, which is decribed as highly effective, but with a painful recovery and side effects such as scar tissue. Quantification of the incidence of this and other side effects of traditional surgery would be useful. The story is clear that the FDA approved the device but that it still needs to undergo further study via randomized controlled trials. Story mentions that this is a new procedure only offerred by 100 doctors. This story is a blananced presentation of sinuplasty and the information here does not appear to be from a press release. The are quotes from otolaryngologists not affliated with the makers of the device who are able to provide perspective on the new sinuplasty procedure. Claim: A balloon instead of a knife: Sinuplasty for ailing sinuses

A: This story provides a good balance of information on a new treatment option for chronic sinusitis, and there is corroboration with otolaryngologists not affiliated with the makers of the balloon device who are able to provide perspective on the procedure. The story clearly notes this procedure would be for chronic, not acute sinusitis and describes how these are different. The story explains that this form of sinuplasty is not for everybody, and that it may not prevent the need for more comprehensive surgery in which bone and inflamed tissue are removed to open the sinus passages. More information is needed on the safety and efficacy of balloon sinuplasty, and no one knows if this surgery works as well as traditional surgery for chronic sinusitis. The story mentions other options for treating chronic sinusitis, including medication and sinus surgery, which is described as highly effective, but with a painful recovery and side effects such as scar tissue. Quantification of the incidence of side effects with traditional surgery would be useful. While there is not much quantitative evidence available on the new procedure, the story stresses the importance of a randomized trial underway comparing medication, traditional sinus surgery and the newer balloon sinuplasty. There is adequate description of this trial and the need for further evidence before this new procedure can be widely recommended. There is a caveat that this procedure should not have been FDA approved with so little quality evidence: a study of 10 people that found “no safety concerns”, but readers should be told more about this very small group. What were the long term outcomes and did these patients eventually have to undergo further sinuplasty, more invasive surgery or continue to take medications to relieve their chronic sinusitis? The story explains that general anesthesia is still needed for the balloon procedure and this comes with its own set of health risks and additional costs. There is no mention of the cost of this newer procedure. This is important information if the surgery is not a permanent fix for chronic sinusitis. A cost comparison of the newer sinuplasty, which may require repeated operations, sinus medications and traditional surgery is needed.
****
Q: Paragraph: “The woman had experienced symptoms and was later hospitalised” before succumbing to the illness, said Ibrahim Melhem, a spokesman for the Palestinian Authority, which has limited self-rule in the West Bank. The woman was from Bidu, a Palestinian village north of Jerusalem and southwest of Ramallah, Melhem added. There are 62 confirmed coronavirus cases among Palestinians in the West Bank, and two in the Gaza Strip. Claim: Palestinians report first death from coronavirus.

A: The Palestinians reported their first death from the coronavirus on Wednesday, a woman in her 60s who lived in the Israeli-occupied West Bank.
****
Q: Paragraph: The Food and Drug Administration cleared a near-copy of the drug, dubbed Amjevita, developed by Amgen Inc. Regulators approved the drug for more than a half-dozen conditions listed on the original drug’s label, including severe psoriasis and Crohn’s diseases. Humira posted sales of nearly $15 billion in 2015 and was for many years the top-selling prescription drug in the world, according to data from IMS Health. It’s the fourth time that the FDA has formally approved a so-called biosimilar, the industry term for a lower-cost version of a biotech drug. Biosimilar drugs, long available in Europe, are thought to have the potential to generate billions in savings for the U.S. health system. But currently only one biosimilar cleared by the FDA approval pathway is actually on the market in the U.S., Novartis’ Zarxio, an alternative to Amgen’s Neupogen that sells for about 15 percent less than the original product. The drug helps boost red blood cells in cancer patients. Amgen did not discuss plans for the drug’s launch or price in a release issued Friday evening. But Wall Street analysts have noted that AbbVie claims it holds patents protecting Humira until at least 2022. They have previously estimated that Amgen’s version could launch sometime between 2018 and 2022, depending on the outcome of court litigation. First approved in 2002, Humira accounted for 60 percent of AbbVie’s total revenue last year. The injectable drug, which blocks chemicals linked to inflammation, is part of a family of biotech drugs including Enbrel and Remicade, which are also facing pending biosimilar competition. Development of lower-cost anti-inflammatory drugs is considered pivotal in reducing U.S. spending on specialty drugs, which has doubled to $150 billion since 2010, according to IMS Health. Thousand Oaks, California-based Amgen is itself a biotech powerhouse, and it too has medications facing competition from cheaper versions. The company is working to hedge those loses by developing lower-cost versions of competitors’ drugs. AbbVie Inc. is based in North Chicago, Illinois. Claim: FDA approves lower-cost alternative to biotech drug Humira.

A:
Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.
****